4D Molecular Therapeutics Grants 66,900 RSUs to Seven New Hires
FDMT•4D Molecular Therapeutics granted 66,900 restricted stock units to seven new non-executive employees under its 2025 Employment Inducement Award Plan on June 9, 2026. The compensation committee approved the awards under Nasdaq Rule 5635(c)(4) as inducements for employment.
1. RSU Grant Details
On June 9, 2026, the compensation committee of 4D Molecular Therapeutics approved grants totaling 66,900 restricted stock units for seven new non-executive employees under the company’s 2025 Employment Inducement Award Plan. These awards were issued in compliance with Nasdaq Rule 5635(c)(4) to attract and retain key talent.
2. Plan Purpose and Structure
The 2025 Employment Inducement Award Plan was established to provide equity incentives to new hires joining 4D Molecular Therapeutics. The plan allows the company to grant RSUs without shareholder approval when recruiting employees whose skills are critical to advancing its pipeline.
3. Company Pipeline
4D Molecular Therapeutics is advancing its lead candidate, 4D-150, through Phase 3 trials for wet age-related macular degeneration and exploring diabetic macular edema, while also developing 4D-710 for cystic fibrosis gene delivery. None of the company’s product candidates have received regulatory approval to date.
